undamentalytics Newsletter
Sign in

Xilio Therapeutics, Inc. revenue

Xilio Therapeutics, Inc.'s revenue was $43.8m in fiscal 2025, up 589.9% on the year before. Over the last twelve months it was $64.1m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Revenue64464
Growth on the year before—+589.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Xilio Therapeutics, Inc. $64.1m 327.3% —
Clinuvel Pharmaceuticals Ltd $64.3m 5.2% —
Abcellera Biologics Inc. $66.2m 101.3% -23.0%
Cytokinetics Inc $67.7m -21.1% 89.5%
Recursion Pharmaceuticals, Inc. $68.2m 56.2% 12.9%
Intellia Therapeutics, Inc. $59.5m 12.6% 3.9%

Compare with peers

Head to head: CUVL vs XLOABCL vs XLOCYTK vs XLO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Xilio Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xilio Therapeutics, Inc.